Literature DB >> 25984438

Interleukin-6 and microRNA profiles induced by oral bacteria in human atheroma derived and healthy smooth muscle cells.

Tanja Pessi1, Leena E Viiri2, Emma Raitoharju3, Nagora Astola2, Ilkka Seppälä3, Melanie Waldenberger4, Kari Lounatmaa5, Alun H Davies2, Terho Lehtimäki3, Pekka J Karhunen3, Claudia Monaco2.   

Abstract

BACKGROUND: Atherosclerosis is an inflammatory disease with possible contributions from bacterial antigens. We aimed to investigate the role of oral bacteria as inducers of inflammatory cascades in smooth muscle cells from carotid endarterectomy patients (AthSMCs) and healthy controls (HSMCs).
FINDINGS: Inactivated Streptococcus mitis, S. sanguinis, S. gorgonii, Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis were used to stimulate inflammation in HSMCs and AthSMCs. Tumor necrosis factor-α (TNFα) was used as a positive control in all stimulations. Interleukin-6 (IL-6) levels were determined from cell culture supernatants and microRNA expression profiles from cells after 24 h of bacterial stimulation. Genome wide expression (GWE) analyses were performed after 5 h stimulation. All studied bacteria induced pro inflammatory IL-6 production in both SMCs. The most powerful inducer of IL-6 was A. actinomycetemcomitans (p < 0.001). Of the 84 studied miRNAs, expression of 9 miRNAs differed significantly (p ≤ 0.001) between HSMCs and AthSMCs stimulated with inactivated bacteria or TNFα. The data was divided into two groups: high IL-6 producers (A. actinomytectemcomititans and TNFα) and low IL-6 producers (streptococcal strains and P. gingivalis). The expression of 4 miRNAs (miR-181-5p, -186-5p, -28-5p and -155-5p) differed statistically significantly (p < 0.001) between healthy HSMCs and AthSMCs in the low IL-6 producer group. According to multidimensional scaling, two gene expression clusters were seen: one in HSMCs and one AthSMCs.
CONCLUSIONS: Our results suggest that inactivated oral bacteria induce inflammation that is differently regulated in healthy and atherosclerotic SMCs.

Entities:  

Keywords:  Atherosclerosis; Genome wide expression; Inflammation; Oral bacteria; Smooth muscle cells; microRNA

Year:  2015        PMID: 25984438      PMCID: PMC4424225          DOI: 10.1186/s40064-015-0993-8

Source DB:  PubMed          Journal:  Springerplus        ISSN: 2193-1801


Introduction

Vascular smooth muscle cells (VSMCs) are highly differentiated muscle cells that form the medial layer of the vessel wall and control blood pressure by contracting and relaxing the vessels. SMCs play an important role in atherogenesis, including a key role in remodeling and plaque stabilization (Doran et al. 2008). Multiple microRNAs (miRNAs), small non-protein-coding RNAs, are known to control the different phases of atherogenesis (reviewed in (Nazari-Jahantigh et al. 2012)). They are responsible for VSMC differentiation and proliferation under physiological or pathological conditions as well as modulating both adaptive and innate immune responses within SMC by encompassing every step from plaque formation to destabilization and rupture (Kang and Hata 2012). Although many miRNAs have been linked to atherosclerosis, only a few miRNAs (e.g. miR-21, −146a, −150, −155) have repeatedly been reported (Ma et al. 2013; Raitoharju et al. 2013). Epidemiological studies have demonstrated a strong relationship between atherosclerosis and oral infections (Desvarieux et al. 2005; Desvarieux et al. 2013), possible due to indirect effects mediated through elevated pro inflammatory cytokines and other acute phase proteins. Several previous studies suggest however that oral bacteria can directly penetrate gingival tissues, enter the bloodstream and potentially induce transient bacteremia even after flossing, mastication, and tooth brushing (Li et al. 2000). Of oral pathogens, streptococci and periodontal bacteria are most frequently detected in atherosclerotic samples (Pessi et al. 2013). It is also known that oral pathogens such as Porphyromonas gingivalis and streptococci have the ability to invade human heart endothelial cells in vitro (Deshpande et al. 1998; Nagata et al. 2011) as well as accelerate plaque growth and macrophage invasion (Kesavalu et al. 2012). In our study, we evaluated the role of processed periodontal and endodontic bacteria in atherosclerotic inflammation using SMCs and selected bacterial species found in coronary plaques after heat inactivation (Pessi et al. 2013). Atherosclerotic inflammation was studied by measuring pro inflammatory interleukin-6 (IL-6) levels and gene expression profiles after bacterial stimulation.

Methods

Bacterial strains

Streptococcus mitis ATCC 49456, Streptococcus sanguinis ATCC 10556, Streptococcus gorgonii ATCC 10558, Aggregatibacter actinomycetemcomitans ATCC 700685, Porphyromonas gingivalis ATCC 33277 from stock culture collection (LCG Standards AB, Borås, Sweden) were diluted to 108/ml in sterile phosphate buffered saline (PBS). All bacteria were heat-inactivated and filtered through a 0.45 μm pore size filter (Merck Millipore, Darmstadt, Germany) before being added into cell cultures as previously described (Pessi et al. 1999). These bacterial preparations were stored at −80°C prior to cell culture experiments.

Ex vivo culture of cells isolated from human atherosclerotic plaques and healthy donors

Smooth muscle cells (SMC) were isolated from the carotid endarterectomies of 4 patients undergoing revascularization procedures for symptomatic carotid disease at Charing Cross Hospital, London. SMCs were isolated and cultures produced as in Monaco et al. 2004. Aortic SMCs from 2 healthy donors (HSMCs) were purchased from PromoCell Ltd (Heidelberg, Germany). The study was approved by the Research Ethics Committee (Riverside Research Ethics Committee, London). All patients gave written informed consent according to the Human Tissue Act 2004 (UK). SMCs were grown in SMC growth medium 2 (PromoCell Ltd, Heidelberg, Germany). Viability was monitored with the use of 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium (MTT) (Sigma-Aldrich, Carlsbad, California, USA). After 3–4 passages, SMCs were cultured in Smooth Muscle Cell Growth Medium 2 (PromoCell) either alone or in the presence of each of the bacterial preparations separately at a final concentration of 107, 106 and 105/ml of culture media. Tumor necrosis factor alpha (TNF-α) (InvivoGen, Source BioScience LifeSciences, Nottingham, UK) was used as a positive control at a concentration of 10 ng/ml. After culturing SMCs with or without bacterial stimulation for 24 h, cell culture supernatants were collected for IL-6 measurement, and cell pellets for miRNA expression profiling. Separate experiments were performed for GWE analyses using the same bacterial preparations. Pellets for GWE analyses were collected after 5 h of stimulation.

Interleukin-6 measurements

Cell culture supernatants were removed after 24 hours and stored at −80°C for single-batch cytokine analysis using the DuoSet ELISA Development Systems (R&D Systems, Minneapolis, USA), according to the manufacturer’s instructions. The ELISA detection limit was 2 pg/ml. Experiments were performed in triplicate.

RNA isolation and expression profiling

Total RNA for miRNA and GWE was isolated using the miRNeasy Mini Kit (Qiagen Ltd, Valencia, USA), and miRNA profiling of 84 commonly known miRNAs was performed using miScript miRNA Array (MIHS-001Z, Qiagen) according to the manufacturer’s instructions. Due to its lowest standard deviation between runs, SNORD68 was selected as a housekeeping gene. Samples with a Ct value ≥35 were excluded from analyses. Of 2016 measurements, 17 failures were observed and excluded from further analyses. Whole genome gene expression (GWE) analysis was performed with Illumina DirectHyb HumanHT-12 v4.0 (Illumina, Inc., San Diego, USA) containing 47,231 oligonucleotide probes representing 34,602 genes, and processed according to the manufacturer’s protocol. The normalization was applied by subtracting the signal intensity of each probe in each sample by the mean intensity for that sample across all probes (global mean normalization). After normalization, multidimensional scaling (MDS) was used to illustrate global gene expressions of each sample in two-dimensional spaces (Cox and Cox 2001).

Transmission electron microscopy

To visualize the bacterial processing in SMCs, AthSMCs were selected after 24 h stimulation with S. mitis for electron microscopy (EM, Figure 1) with a JEOL 1200EX transmission electron microscope (Japanese Electron Optics Laboratory, Tokyo, Japan) operating at 60 kV.
Figure 1

Phagocytosis of S. mitis by AthSMCs. Arrows indicate bacteria and their components. Bar is 0.5 μm.

Phagocytosis of S. mitis by AthSMCs. Arrows indicate bacteria and their components. Bar is 0.5 μm.

Statistical analyses

All results (IL-6 levels, miRNA and GWE) were normalized against the corresponding results obtained from cultures without the addition of inactivated bacteria. Due to the skewed distributions and low number of cases, statistical differences between the experiments were calculated using the non-parametric Mann Whitney U test and Spearman’s correlation test. Of IL-6 results p < 0.01 was considered to be statistically significant, and due to the multiple measurements of the miRNA results p ≤ 0.001 was considered statistically significant (PASW Statistical Software version 18; SPSS Ltd, Quarry Bay, Hong Kong, China).

Results

IL-6 production induced by oral bacteria

All studied bacteria (S. mitis, S. sangui, S. gordonii, P. gingivalis, A. actinomycetemcomitans) and TNFα induced IL-6 production in AthSMCs as well as in healthy SMCs (Figure 2). Among bacterial stimulations, the most powerful inducer was A. actinomycetemcomitans (p < 0.001, Mann Whitney U test). IL-6 responses induced by other bacteria did not differ from each other (p>0.01). The effects of bacteria on IL-6 production were dose-dependent in both cell types (data not shown).
Figure 2

The production of IL-6 induced by inactivated oral bacteria at the concentration of 107/ml and TNF-α (10 ng/ml) in healthy SMCs (HSMCs, n = 2) and atheroma derived SMCs (AthSMCs, n = 4). Means (+SD) are expressed as induction folds compared to medium values (no stimulus). Statistically significant differences (*; p = 0.01 and **; p = 0.001) are marked in the figure. S. Streptococcus; P. ging, Porphyromonas gingivalis; A. act, Aggregatibacter actinomycetemcomitans; TNF-α, tumor necrosis factor-α. Red bar represents from AthSMCs results and blue from HSMCs.

The production of IL-6 induced by inactivated oral bacteria at the concentration of 107/ml and TNF-α (10 ng/ml) in healthy SMCs (HSMCs, n = 2) and atheroma derived SMCs (AthSMCs, n = 4). Means (+SD) are expressed as induction folds compared to medium values (no stimulus). Statistically significant differences (*; p = 0.01 and **; p = 0.001) are marked in the figure. S. Streptococcus; P. ging, Porphyromonas gingivalis; A. act, Aggregatibacter actinomycetemcomitans; TNF-α, tumor necrosis factor-α. Red bar represents from AthSMCs results and blue from HSMCs.

miRNA and GWE profiles in SMCs after stimulation

miRNA expression profiles in AthSMCs and HSMCs were studied after 24 h bacterial stimulation. Of the 84 miRNAs, 9 (miR-96-5p, −185-5p, −181b-5p, −200c-3p, −28-5p, −222-3p, −186-5p, let7a-5p and let7e-5p) were statistically significantly differently expressed (Table 1 and Additional file 1: Table S1) in AthSMC and HSMCs after bacterial stimulation (p < 0.001). Since IL-6 levels produced by SMCs after stimulation with A. actinomytectemcomititans significantly differed to IL-6 levels after stimulation with other bacteria, the data was divided into two groups: “high IL-6 producers” i.e. A. actinomytectemcomititans and TNF-α and “low IL-6 producers”, i.e. different streptococci and P. gingivalis. It was observed that in the “low IL-6 producer” group (Figure 3), the expression of 4 miRNAs (miR-181b-5p, −186-5p, −28-5p and −155-5p) differed statistically significantly between HSMCs and AthSMCs (p <0.001; Mann- Whitney U test). The expression of 3 miRNAs (miR-155-5p, −150-5p and −9-5p) correlated with IL-6 levels (p < 0.001, Spearman’s correlation).
Table 1

Fold changes of stimulated miRNAs in healthy and atherosclerotic SMCs

HSMCs AthSMCs
Percentiles Percentiles
miRNA ID Accession number Median 25th 75th Median 25th 75th p-value*
hsa-miR-142-5pMIMAT0000433−1.58−1.980.67−0.05−1.892.08
hsa-miR-9-5pMIMAT0000441−2.31−4.05−1.49−1.51−2.331.710.045
hsa-miR-150-5pMIMAT0000451−2.01−2.69−1.033.18−0.44.310.002
hsa-miR-27b-3pMIMAT0000419−1.25−1.531.05−1.42−1.740.68
hsa-miR-101-3pMIMAT00000993.391.615.331.05−1.472.050.007
hsa-let-7d-5pMIMAT0000065−1.26−1.47−1.051.05−1.071.10.014
hsa-miR-103a-3pMIMAT0000101−0.02−1.321.44−1.07−1.281.1
hsa-miR-16-5pMIMAT0000069−1.32−1.760.48−0.02−1.171.19
hsa-miR-26a-5pMIMAT0000082−1.18−1.41.2−1.78−2.04−1.15
hsa-miR-32-5pMIMAT00000901.22−1.123.44.011.565.69
hsa-miR-26b-5pMIMAT0000083−1.37−1.87−1.08−1.77−2.19−1.32
hsa-let-7 g-5pMIMAT0000414−1.41−1.88−1.18−1.23−1.560.53
hsa-miR-30c-5pMIMAT0000244−1.19−1.521.09−1.71−2.25−1.11
hsa-miR-96-5p MIMAT0000095 −3.54 −4.93 −1.53 1.43 1.13 3.41 <0.001
hsa-miR-185-5p MIMAT0000455 2.07 1.43 3.15 −1.25 −1.3 −1.02 <0.001
hsa-miR-142-3pMIMAT0000434−1.11−1.542.652.181.93.980.014
hsa-miR-24-3pMIMAT00000801.03−1.131.25−1.12−1.481.22
hsa-miR-155-5pMIMAT0000646−1.4−1.63−1.181.06−1.121.310.003**
hsa-miR-146a-5pMIMAT0000449−1.61−2.01−1.17−2.01−2.48−1.32
hsa-miR-425-5pMIMAT00033931.24−0.51.49−1.16−1.650.61
hsa-miR-181b-5p MIMAT0000257 −1.27 −1.39 −1.14 1.13 −0.55 1.34 <0.001**
hsa-miR-302b-3pMIMAT0000715−1.97−3.130.46−1.84−2.83−1.15
hsa-miR-30b-5pMIMAT0000420−1.09−1.31.13−1.25−1.540.6
hsa-miR-21-5pMIMAT0000076−1.69−2.72−1.37−1.98−2.36−1.23
hsa-miR-30e-5pMIMAT00006921.461.092.09−1.15−1.451.180.008
hsa-miR-200c-3p MIMAT0000617 −1.79 −2.51 −1.5 1.47 1.04 2.38 <0.001
hsa-miR-15b-5pMIMAT0000417−1.06−1.291.12−0.09−1.471.24
hsa-miR-223-3pMIMAT0000280−2.6−5.45−1.14−1.48−1.87.44
hsa-miR-194-5pMIMAT00004601.06−1.241.47−1.65−2.010.59
hsa-miR-210-3pMIMAT00002672.651.394.492.021.522.34
hsa-miR-15a-5pMIMAT00000682.071.612.951.14−1.41.80.024
hsa-miR-181a-5pMIMAT00000681.781.332.721.34−1.291.580.028
hsa-miR-125b-5pMIMAT00004231.1−1.111.5−1.51−2.11−1.160.01
hsa-miR-99a-5pMIMAT00000971.07−1.121.41−1.74−2.040.55
hsa-miR-28-5p MIMAT0000085 1.82 1.3 2.13 −1.43 −1.78 1.05 <0.001**
hsa-miR-320aMIMAT0000510−0.02−1.461.221.13−1.051.38
hsa-miR-125a-5pMIMAT0000443−1.48−3.10.55−1.21−1.891.42
hsa-miR-29b-3pMIMAT00001002.021.394.662−1.12.65
hsa-miR-29a-3pMIMAT00000861.43−0.571.86−1.03−1.181.57
hsa-miR-141-3pMIMAT0000432−0.09−1.982.12.08−0.493.03
hsa-miR-19a-3pMIMAT00000731.82−0.513.2−1.06−1.371.69
hsa-miR-18a-5pMIMAT00000720.05−1.191.6−0.04−1.281.13
hsa-miR-374a-5pMIMAT0000727−1.28−1.560.5−1.53−2.1−1.03
hsa-miR-423-5pMIMAT0004748−1.2−1.340.51.21.021.520.002
hsa-let-7a-5p MIMAT0000062 −1.53 −1.9 −1.26 −1.02 −1.13 1.13 0.001
hsa-miR-124-3pMIMAT00004221.15−1.863.061.931.133.97
hsa-miR-92a-3pMIMAT0000092−0.03−1.371.22−1.06−1.131.18
hsa-miR-23a-3pMIMAT0000078−1.34−1.98−1.04−1.5−1.7−1.13
hsa-miR-25-3pMIMAT0000081−1.47−2.14−1.27−1.73−1.97−1.08
hsa-let-7e-5p MIMAT0000066 −1.55 −1.87 −1.26 1.16 −1.04 1.32 <0.001
hsa-miR-376c-3pMIMAT00007202.081.342.73−1.43−1.631.50.006
hsa-miR-126-3pMIMAT00004451.2−1.081.98−0.09−1.521.44
hsa-miR-144-3pMIMAT0000436−2.07−3.781.881.21−1.493.64
hsa-miR-424-5pMIMAT0001341−1.46−2.18−1.09−1.63−1.780.44
hsa-miR-30a-5pMIMAT00000871.61.12.06−0.03−1.241.35
hsa-miR-23b-3pMIMAT0000418−1.5−1.990.48−1.24−1.610.5
hsa-miR-151a-5pMIMAT0004697−0.01−1.211.35−1.59−2.01−1.130.02
hsa-miR-195-5pMIMAT0000461−1.07−1.270.531.221.131.450.005
hsa-miR-143-3pMIMAT00004352.261.854.341.28−0.52.15
hsa-miR-30d-5pMIMAT00002450.02−1.481.42−1.14−1.381.15
hsa-miR-191-5pMIMAT0000440−1.1−1.241.23−1.47−1.730.53
hsa-let-7i-5pMIMAT00004151.151.081.411.1−1.161.32
hsa-miR-302a-3pMIMAT0000684−1.06−1.191.4−1.25−1.851.13
hsa-miR-222-3p MIMAT0000279 1.4 −0.53 1.85 −1.52 −1.65 0.55 <0.001
hsa-let-7b-5pMIMAT00000631.14−1.091.421.961.532.140.002
hsa-miR-19b-3pMIMAT00000741.64−1.43.140.07−1.151.67
hsa-miR-17-5pMIMAT00000701.631.262.28−1.02−1.321.30.002
hsa-miR-93-5pMIMAT00000931.23−1.182.450.01−1.451.35
hsa-miR-186-5p MIMAT0000456 −1.94 −2.44 −1.37 1.34 −0.54 1.64 <0.001**
hsa-miR-196b-5pMIMAT00010801.46−3.147.091.81−1.246.42
hsa-miR-27a-3pMIMAT00000841.33−0.541.65−1.04−1.341.36
hsa-miR-22-3pMIMAT00000772.421.444.241.35−0.62.190.003
hsa-miR-130a-3pMIMAT00004251.61.152.062.05−0.63.12
hsa-let-7cMI0000064−1.2−1.351.170.01−1.081.57
hsa-miR-29c-3pMIMAT00006811.41−0.531.841.04−1.341.25
hsa-miR-140-3pMIMAT00045971.69−0.573.06−1.24−1.621.10.008
hsa-miR-128-3pMIMAT0000424−1.18−1.480.58−1.44−1.730.48
hsa-let-7f-5pMIMAT0000067−1.6−1.91−1.39−1.4−2.02−1.14
hsa-miR-122-5pMIMAT0000421−1.84−4.05−1.011.65−0.593.240.028
hsa-miR-20a-5pMIMAT00000751.36−0.532−1.38−1.560.530.004
hsa-miR-106b-5pMIMAT00006802.06−0.412.69−0.03−1.271.230.006
hsa-miR-7-5pMIMAT0000252−1.53−2.98−1.37−1.45−2.610.49
hsa-miR-100-5pMIMAT0000098−1.05−1.361.19−1.85−2.091.05
hsa-miR-302c-3pMIMAT0000717−1.17−1.743.621.91.22.27

*Mann–Whitney U test.

**When data was divided into low and high IL-6 stimulants, highly significant results (P < 0.001) were observed in the group of low IL-6 stimulants, like streptococci and P. gingivalis (see Figures 2 and 3).

Fold changes calculated using unstimulated cells as a reference. The data from different stimuli (streptococci, P. gingivalis, A. actinomytectemcomititans or TNFα) were pooled and median values presented with 25th and 75th interquartile ranges. P-values < 0.05 are presented. P-values < 0.001 in bold.

Figure 3

Fold changes of miRNAs (A; miR-181b-5p, B;186-5p, C; 28-5p, D;155-5p, E;150-5p, F; 9-5p) and IL-6 levels after streptococci or P. gingivalis stimulation in healthy SMCs (HSMCs) and atheroma derived SMCs (AthSMCs). N-fold difference compared to corresponding values from cultures without bacteria. Each stimulation was performed twice, red circles represent AthSMCs results and blue circles from HSMCs.

Fold changes of stimulated miRNAs in healthy and atherosclerotic SMCs *Mann–Whitney U test. **When data was divided into low and high IL-6 stimulants, highly significant results (P < 0.001) were observed in the group of low IL-6 stimulants, like streptococci and P. gingivalis (see Figures 2 and 3). Fold changes calculated using unstimulated cells as a reference. The data from different stimuli (streptococci, P. gingivalis, A. actinomytectemcomititans or TNFα) were pooled and median values presented with 25th and 75th interquartile ranges. P-values < 0.05 are presented. P-values < 0.001 in bold. Fold changes of miRNAs (A; miR-181b-5p, B;186-5p, C; 28-5p, D;155-5p, E;150-5p, F; 9-5p) and IL-6 levels after streptococci or P. gingivalis stimulation in healthy SMCs (HSMCs) and atheroma derived SMCs (AthSMCs). N-fold difference compared to corresponding values from cultures without bacteria. Each stimulation was performed twice, red circles represent AthSMCs results and blue circles from HSMCs. Multidimensional scaling (MDS) from GWE data was performed for illustrative purposes to evaluate global expression of stimulated genes in SMCs (Figure 4). Global gene expression profiles were similar for samples stimulated with oral bacteria within the same SMC type with the exception of by A. actinomycetemcomitans in HSMCs. Two expression profile cluster were observed according to cell type: HSMC and AthSMC. This difference was clearly seen in dimension 1 vs. 2 (Figure 4) as well as in dimension 1 vs. 3 (data not shown).
Figure 4

Dimensions 1 and 2 from the multidimensional scaling (MDS) of GWE data in healthy SMCs (HSMCs) and atheroma derived SMCs (AthSMCs) stimulated with oral bacteria and tumor necrosis factor (TNF)-α, S., Streptococcus; P., Porphyromonas; A., Aggregatibacter. Red circles represent AthSMCs results and blue from HSMCs.

Dimensions 1 and 2 from the multidimensional scaling (MDS) of GWE data in healthy SMCs (HSMCs) and atheroma derived SMCs (AthSMCs) stimulated with oral bacteria and tumor necrosis factor (TNF)-α, S., Streptococcus; P., Porphyromonas; A., Aggregatibacter. Red circles represent AthSMCs results and blue from HSMCs.

Discussion and conclusion

The present results confirm that the studied attenuated oral bacteria have the ability to activate a pro-inflammatory response in vascular smooth muscle cells. A. actinomycetemcomitans was the most potent inducer of inflammation and differed from other bacteria in its capacity to induce inflammation. This was seen in both IL-6 levels and gene expression profiles. After bacterial stimulation miRNA profiles were different in atherosclerotic SMCs and in healthy SMCs, which has not been studied before. The down regulation of miR-185-5p after bacterial stimulation in AthSMCs was in line with studies on carotid plaques without bacterial stimulation (Raitoharju et al. 2011; Raitoharju et al. 2013) suggesting that bacterial stimulation per se does not change the direction of miRNA expression. Expression levels (with or without bacterial stimulation) of other 8 miRNAs (miR-96-5p, −181b-5p, −185-5p, −200c-3p, −222-3p, −28-5p, let-7a-5p) in atherosclerotic tissues have not been identified before (see supplement summary), however their characterized functions (explained in the Additional file 1: Table S1) support their involvement in atherosclerotic inflammation. miRNA results from ‘the low-IL-6 producers’, i.e. stimulation with streptococci and P. gingivalis were separately evaluated. Our result show down-regulation of miR 28-5p, which may result in the enhancement of several inflammatory markers and adhesion molecules, as suggested by Stather et al. (2013). We also detected upregulated miR-181b-5p and −186-5p, which may suppress plasminogen activator inhibitor-1 in VSMCs (Chen et al. 2014) and promote apoptosis (Zhou et al. 2008), thus interfering with extracellular matrix degradation, and structural and functional changes in VSMCs. miR-155 is highly expressed in various cell types including VSMCs and endothelial cells (Faraoni et al. 2009). It changes endothelial cell morphology and modulates the endothelial phenotype via re-organizing the actin cytoskeleton (Weber et al. 2014). Upregulated miR-155 also attenuates endothelial cell migration, proliferation, and apoptosis in atherosclerotic plaques (Weber et al. 2014). miR-155-5p was highly expressed in AthSMCs after bacterial stimulation and its expression also correlated with IL-6 levels, suggesting a potential role for this miRNA in bacterial-induced atherosclerotic inflammation. Multidimensional scaling (MDS) summarizes genome wide expression (GWE) data of each sample and displays a structure of distance-like data as a geometrical picture illustrating similarities or dissimilarities between each sample (Cox and Cox 2001). Dots in the picture of dimensions 1 vs. 2 demonstrate major variances occurring in global gene expressions. Dots in MDS figures do not, however, explain which and how many genes are differently expressed. Two major clusters were seen here, i.e. one among HSMCs and one among AthSMCs. This is in line with our findings observed in the miRNA profiles. Although our study is a pilot study with limited numbers, it is a novel study looking at the effects of attenuated oral bacteria in inducing inflammation in both healthy and atherosclerotic SMCs. No previous studies have combined both traditional inflammatory markers, like IL-6, as well as newly discovered gene expression markers in bacterial-induced atherosclerosis. The relatively low expression levels induced by attenuated bacteria may indicate that certain bacterial antigens from attenuated bacterial cells could have some role in smouldering atherosclerotic inflammation.
  20 in total

Review 1.  Systemic diseases caused by oral infection.

Authors:  X Li; K M Kolltveit; L Tronstad; I Olsen
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  The role of microRNAs in arterial remodelling.

Authors:  M Nazari-Jahantigh; Y Wei; A Schober
Journal:  Thromb Haemost       Date:  2012-02-28       Impact factor: 5.249

3.  Differential microRNA expression profiles in peripheral arterial disease.

Authors:  Philip W Stather; Nicolas Sylvius; John B Wild; Edward Choke; Robert D Sayers; Matthew J Bown
Journal:  Circ Cardiovasc Genet       Date:  2013-10

4.  Increased atherogenesis during Streptococcus mutans infection in ApoE-null mice.

Authors:  L Kesavalu; A R Lucas; R K Verma; L Liu; E Dai; E Sampson; A Progulske-Fox
Journal:  J Dent Res       Date:  2012-01-18       Impact factor: 6.116

5.  Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts.

Authors:  Emma Raitoharju; Ilkka Seppälä; Mari Levula; Pekka Kuukasjärvi; Jari Laurikka; Kjell Nikus; Ari-Pekka J Huovila; Niku Oksala; Norman Klopp; Thomas Illig; Reijo Laaksonen; Pekka J Karhunen; Jari Viik; Rami Lehtinen; Markku Pelto-Huikko; Matti Tarkka; Mika Kähönen; Terho Lehtimäki
Journal:  Atherosclerosis       Date:  2011-05-13       Impact factor: 5.162

Review 6.  MicroRNA-155 in the pathogenesis of atherosclerosis: a conflicting role?

Authors:  Xiaochun Ma; Chi Ma; Xia Zheng
Journal:  Heart Lung Circ       Date:  2013-07-01       Impact factor: 2.975

7.  Invasion of human aortic endothelial cells by oral viridans group streptococci and induction of inflammatory cytokine production.

Authors:  E Nagata; A de Toledo; T Oho
Journal:  Mol Oral Microbiol       Date:  2010-12-03       Impact factor: 3.563

Review 8.  MicroRNAs in the atherosclerotic plaque.

Authors:  Emma Raitoharju; Niku Oksala; Terho Lehtimäki
Journal:  Clin Chem       Date:  2013-05-31       Impact factor: 8.327

9.  Changes in clinical and microbiological periodontal profiles relate to progression of carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology study.

Authors:  Moïse Desvarieux; Ryan T Demmer; David R Jacobs; Panos N Papapanou; Ralph L Sacco; Tatjana Rundek
Journal:  J Am Heart Assoc       Date:  2013-10-28       Impact factor: 5.501

10.  Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy.

Authors:  Yan-Shan Chen; Ling Shen; Rui-Qin Mai; Ying Wang
Journal:  Exp Ther Med       Date:  2014-09-02       Impact factor: 2.447

View more
  3 in total

1.  Characterization of smooth muscle cells from human atherosclerotic lesions and their responses to Notch signaling.

Authors:  Jessica Davis-Knowlton; Jacqueline E Turner; Anna Turner; Sydney Damian-Loring; Nicholas Hagler; Terry Henderson; Ivette F Emery; Kyle Bond; Christine W Duarte; Calvin P H Vary; Jens Eldrup-Jorgensen; Lucy Liaw
Journal:  Lab Invest       Date:  2018-05-23       Impact factor: 5.662

2.  Interactions Between IL-17 Variants and Streptococcus in the Gut Contribute to the Development of Atopic Dermatitis in Infancy.

Authors:  Mi Jin Kang; So Yeon Lee; Yoon Mee Park; Bong Soo Kim; Min Jung Lee; Jeong Hyun Kim; Seonmi Jeong; Seung Hwa Lee; Min Jee Park; Eun Sang Rhee; Sungsu Jung; Jisun Yoon; Hyun Ju Cho; Eun Lee; Song I Yang; Dong In Suh; Kyung Won Kim; Youn Ho Sheen; Kangmo Ahn; Soo Jong Hong
Journal:  Allergy Asthma Immunol Res       Date:  2021-05       Impact factor: 5.764

3.  Fucoidan-Mediated Inhibition of Fibrotic Properties in Oral Submucous Fibrosis via the MEG3/miR-181a/Egr1 Axis.

Authors:  Chih-Yuan Fang; Szu-Han Chen; Chun-Chung Huang; Yi-Wen Liao; Shih-Chi Chao; Cheng-Chia Yu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.